about
Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study.Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infectionA focus reduction neutralization assay for hepatitis C virus neutralizing antibodiesOptimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA ImmunizationConserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goatsMitigating the looming vaccine crisis: production and delivery of plasmid-based vaccinesDevelopment of a heterologous, multigenotype vaccine against hepatitis C virus infection.Experimental and emerging therapies for chronic hepatitis C virus infection.Epidemiology and prophylaxis of viral hepatitis: a global perspective.A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanismsEvaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combinationDevelopment of prophylactic and therapeutic vaccines against hepatitis C virus.Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNATCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsAssociation of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients.HCV: Written in our DNA.
P2860
Q24800271-53C174E1-9861-4BED-83BF-D5569934CC43Q24815995-005E331C-3EB4-4297-8E9C-DB23748818CAQ27478125-BF7E21F9-10D7-487A-ABBD-2E0081BC702FQ27478295-1CBA14DF-1CEA-4585-9BE2-C225E179279BQ27485755-74FD7E1F-F42D-4CB5-A256-5743A86F8F11Q27488724-6D96EC8B-F090-459B-830C-05B66671D80BQ28294355-F5E5E67B-1FC5-4155-9B4E-DB723F522D07Q33282900-00F3EB23-8828-4EFA-8DEB-F6756FDF6373Q34481629-317A250A-FB0B-4318-82B2-2791881B7427Q34631380-EBBC1CA9-6FD8-42DC-8883-0F193770AF7CQ35895400-885452F3-B9D6-4348-A266-9810B64903C8Q35950879-D8ACC29A-D930-4CF8-8FD4-855CBFBE0C5DQ36198667-73C2208E-7FFF-4969-ADD6-6B1BB85AADFCQ36280098-F8FCF496-45E5-4FA5-8E70-6947D710C6F9Q36951685-1C7C46DC-6FFD-4DE9-920C-B01C387C04FAQ37277880-E6203BDB-1137-4367-8DE1-3C2E450C8FF9Q40751217-D274767A-EDA0-46A8-AADC-1209706FBF7D
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Vaccine development for hepatitis C.
@ast
Vaccine development for hepatitis C.
@en
Vaccine development for hepatitis C.
@nl
type
label
Vaccine development for hepatitis C.
@ast
Vaccine development for hepatitis C.
@en
Vaccine development for hepatitis C.
@nl
prefLabel
Vaccine development for hepatitis C.
@ast
Vaccine development for hepatitis C.
@en
Vaccine development for hepatitis C.
@nl
P356
P1476
Vaccine development for hepatitis C.
@en
P2093
P304
P356
10.1055/S-2000-9947
P577
2000-01-01T00:00:00Z